PAISTE

Paste Bio is a next-generation gene editing company focused on developing a platform for large-scale gene insertion. The company utilizes its proprietary PASTE (Programmable Addition via Site-specific Targeting Elements) technology, which combines CRISPR-based targeting with integrases to insert large DNA sequences into the genome without causing double-stranded breaks. This approach aims to treat a wide range of genetic diseases by replacing or supplementing entire genes, potentially offering a more versatile solution than traditional gene editing methods. Founded by pioneers in the field, Paste Bio is currently in the pre-clinical stage, advancing its pipeline toward therapeutic applications in areas such as cystic fibrosis and other monogenic disorders.